SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-24-001349
Filing Date
2024-02-06
Accepted
2024-02-06 08:56:32
Documents
18
Period of Report
2024-02-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tenx_8k.htm   iXBRL 8-K 25015
2 PRESS RELEASE tenx_ex991.htm EX-99.1 17964
8 tenx_ex991img2.jpg GRAPHIC 2877
  Complete submission text file 0001654954-24-001349.txt   176640

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tenx-20240206.xsd EX-101.SCH 5720
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20240206_lab.xml EX-101.LAB 14667
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tenx-20240206_cal.xml EX-101.CAL 898
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20240206_pre.xml EX-101.PRE 9275
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tenx-20240206_def.xml EX-101.DEF 2099
19 EXTRACTED XBRL INSTANCE DOCUMENT tenx_8k_htm.xml XML 3910
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

IRS No.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 24598243
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)